Universe Pharmaceuticals Inc
UPC4.290USD
+0.560+15.01%
收盤 12/24, 13:00（美東）報價延遲15分鐘
2.42M總市值
0.00本益比TTM
關於 Universe Pharmaceuticals Inc 公司
Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.
Universe Pharmaceuticals Inc簡介
公司代碼UPC
公司名稱Universe Pharmaceuticals Inc
上市日期Mar 23, 2021
CEOLai (Gang)
員工數量225
證券類型Ordinary Share
年結日Mar 23
公司地址265 Jingjiu Avenue
城市JI'AN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家China
郵編343100
電話867968403309
網址http://www.universe-pharmacy.com/
公司代碼UPC
上市日期Mar 23, 2021
CEOLai (Gang)
Universe Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Gang Lai
Mr. Gang Lai
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Lin Yang
Ms. Lin Yang
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Baochang Liu
Mr. Baochang Liu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jiawen Pang
Mr. Jiawen Pang
Independent Director
Independent Director
--
--
Mr. H. David Sherman
Mr. H. David Sherman
Independent Director
Independent Director
--
--
Mr. Ding Zheng
Mr. Ding Zheng
Independent Director
Independent Director
--
--
Ms. Tina Xiao
Ms. Tina Xiao
IR Contact Officer
IR Contact Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Gang Lai
Mr. Gang Lai
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Lin Yang
Ms. Lin Yang
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Baochang Liu
Mr. Baochang Liu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jiawen Pang
Mr. Jiawen Pang
Independent Director
Independent Director
--
--
Mr. H. David Sherman
Mr. H. David Sherman
Independent Director
Independent Director
--
--
Mr. Ding Zheng
Mr. Ding Zheng
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Sales of TCMD products
14.03M
60.92%
Sales of third-party products
9.00M
39.08%
地區USD
名稱
營收
佔比
China (Mainland)
23.02M
100.00%
業務
地區
業務USD
名稱
營收
佔比
Sales of TCMD products
14.03M
60.92%
Sales of third-party products
9.00M
39.08%
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Sununion Holding Group Ltd
0.62%
Osaic Holdings, Inc.
0.35%
其他
99.03%
持股股東
持股股東
佔比
Sununion Holding Group Ltd
0.62%
Osaic Holdings, Inc.
0.35%
其他
99.03%
股東類型
持股股東
佔比
Corporation
0.62%
Investment Advisor
0.36%
其他
99.03%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
14
--
0.00%
-15.11K
2025Q2
15
3.73K
0.66%
-14.56K
2025Q1
15
3.73K
8.84%
-14.56K
2024Q4
15
702.49K
4.61%
+518.42K
2024Q3
12
183.86K
3.78%
+44.54K
2024Q2
8
139.13K
0.94%
-3.04K
2024Q1
8
138.86K
57.13%
-3.66K
2023Q4
9
139.20K
57.27%
-3.80K
2023Q3
13
139.26K
57.29%
-143.15K
2023Q2
13
139.86K
57.87%
-142.30K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Sununion Holding Group Ltd
3.47K
0.62%
--
--
Apr 29, 2025
UBS Financial Services, Inc.
--
0%
-266.00
-100.00%
Jun 30, 2025
StoneX Group Inc.
--
0%
-25.00
-100.00%
Dec 31, 2024
Sabby Management, LLC
--
0%
-8.33K
-100.00%
Mar 31, 2025
Anson Funds Management LP.
--
0%
-5.76K
-100.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
--
0%
-2.00
-100.00%
Mar 31, 2025
MML Investors Services, LLC
--
0%
-390.00
-100.00%
Dec 31, 2024
Quadrature Capital LLP
--
0%
-41.00
-100.00%
Dec 31, 2024
Virtu Americas LLC
--
0%
-28.00
-100.00%
Dec 31, 2024
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 20, 2025
Merger
40→1
Mar 20, 2025
Merger
40→1
Mar 20, 2025
Merger
40→1
Mar 20, 2025
Merger
40→1
Nov 14, 2024
Merger
15→1
Nov 14, 2024
Merger
15→1
公告日期
類型
比率
Mar 20, 2025
Merger
40→1
Mar 20, 2025
Merger
40→1
Mar 20, 2025
Merger
40→1
Mar 20, 2025
Merger
40→1
Nov 14, 2024
Merger
15→1
Nov 14, 2024
Merger
15→1
Nov 14, 2024
Merger
15→1
Nov 14, 2024
Merger
15→1
Jul 27, 2023
Merger
6→1
Jul 27, 2023
Merger
6→1
查看更多
常見問題
Universe Pharmaceuticals Inc的前五大股東是誰？
Universe Pharmaceuticals Inc的前五大股東如下：
Sununion Holding Group Ltd持有股份：3.47K佔總股份比例：0.62%。
UBS Financial Services, Inc.持有股份：0.00佔總股份比例：0.00%。
StoneX Group Inc.持有股份：0.00佔總股份比例：0.00%。
Sabby Management, LLC持有股份：0.00佔總股份比例：0.00%。
Anson Funds Management LP.持有股份：0.00佔總股份比例：0.00%。
Sununion Holding Group Ltd持有股份：3.47K佔總股份比例：0.62%。
UBS Financial Services, Inc.持有股份：0.00佔總股份比例：0.00%。
StoneX Group Inc.持有股份：0.00佔總股份比例：0.00%。
Sabby Management, LLC持有股份：0.00佔總股份比例：0.00%。
Anson Funds Management LP.持有股份：0.00佔總股份比例：0.00%。
Universe Pharmaceuticals Inc的前三大股東類型是什麼？
Universe Pharmaceuticals Inc 的前三大股東類型分別是：
Sununion Holding Group Ltd
Osaic Holdings, Inc.
其他
Sununion Holding Group Ltd
Osaic Holdings, Inc.
其他
有多少機構持有Universe Pharmaceuticals Inc(UPC)的股份？
截至2025Q3，共有14家機構持有Universe Pharmaceuticals Inc的股份，合計持有的股份價值約為--，占公司總股份的--% 。與2025Q2相比，機構持股有所增加，增幅為-0.66%。
哪個業務部門對Universe Pharmaceuticals Inc的收入貢獻最大？
在FY2024，Sales of TCMD products業務部門對Universe Pharmaceuticals Inc的收入貢獻最大，創收14.03M，占總收入的60.92% 。
